NES
NBSE

New England Securities’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

New England Securities’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$33K Hold
10
– – 0.01% 711
2014
Q3 		$29K Hold
10
– – 0.01% 787
2014
Q2 		$38K Buy
+10
New +$37.6K 0.01% 691

Other funds holding NBSE

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

New England Securities's NBSE Position: Q4 2014 in Review

New England Securities held its NeuBase Therapeutics, Inc. Common Stock (NBSE) position steady in Q4 2014 at 10 shares worth $33K. The position accounts for 0.01% of the portfolio, ranked #711.

New England Securities first reported a position in NBSE in Q2 2014 and has held it in 3 quarters since. The position peaked at $38K in Q2 2014. 53 funds tracked by Wall St. Rank hold NBSE as of Q4 2014.

  • New England Securities held 10 shares of NeuBase Therapeutics, Inc. Common Stock worth $33K as of Q4 2014.
  • New England Securities left its NeuBase Therapeutics, Inc. Common Stock share count unchanged in Q4 2014.
  • NeuBase Therapeutics, Inc. Common Stock made up 0.01% of New England Securities's portfolio in Q4 2014, its #711 holding.
  • New England Securities first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and has held it in 3 quarters since.
  • New England Securities's NeuBase Therapeutics, Inc. Common Stock position peaked at $38K in Q2 2014.
  • 53 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2014.

Based on New England Securities's 13F filing for Q4 2014, filed 26 Jan 2015.